Kelley Baumhover
Optometrist · West Des Moines, IANPI 1104874643
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 25.9% of the total. 2025 is the largest year on record at $901, 4.3 times the $212 reported in 2019. Among optometrist clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$911
- Mallinckrodt Hospital Products Inc.$467
- Sun Pharmaceutical Industries Inc.$313
- Tarsus Pharmaceuticals, Inc.$246
- Bausch & Lomb Americas Inc.$232
- Bausch & Lomb, A Division Of Bausch Health US, LLC$221
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,42297%
- Education$983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $911 |
| Mallinckrodt Hospital Products Inc. | 16 | $467 |
| Sun Pharmaceutical Industries Inc. | 17 | $313 |
| Tarsus Pharmaceuticals, Inc. | 12 | $246 |
| Bausch & Lomb Americas Inc. | 12 | $232 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $221 |
| Alcon | 11 | $216 |
| Oyster Point Pharma, Inc. | 8 | $175 |
| Amgen(2 entities) | 10 | $165 |
| The Cameron-ehlen Group, Inc. | 2 | $140 |
| Novartis | 7 | $124 |
| Sight Sciences, Inc. | 3 | $53 |
| Coopervision Inc. | 2 | $52 |
| Dompe US, Inc. | 2 | $40 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| Rayner Intraocular Lenses Limited | 2 | $34 |
| Thea Pharma Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Glaukos Corporation | 1 | $15 |
| Alimera Sciences, Inc. | 1 | $13 |
How this compares
$3,520 in reported general payments places this provider in the 95th percentile of 559 optometrist providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $71,308 |
| VyzultaLatanoprostene Bunod | 40 | $18,357 |
| XiidraLifitegrast | 13 | $17,340 |
| LumiganBimatoprost | 21 | $14,191 |
| MieboPerfluorohexyloctane/Pf | 11 | $11,062 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $7,868 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 44 | $7,572 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,430 |
| Travoprost | 13 | $1,968 |
| Doxycycline Hyclate | 44 | $1,513 |
| ValacyclovirValacyclovir Hcl | 26 | $911 |
| Latanoprost | 111 | $868 |
| Loteprednol Etabonate | 11 | $839 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 52 | $783 |
| Prednisolone Acetate | 20 | $772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $911 | $93,36899 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $232 | $46,75964 claims |
| AlconSimbrinza | $216 | $3,43016 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $221 | $83911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 optometrist providers in Iowa.
Other optometrist in West Des Moines
- Kelsi SawatzkyWest Des Moines$26K
- Lexie FranzeenWest Des Moines$7K
- Jenessa LockWest Des Moines$5K
- Michael LockWest Des Moines$4K
- Barbara ScheetzWest Des Moines$3K
- Sara ButterworthCoralville$191K
- Ethan HuismanWaukee$111K
- Heidi BellClive$19K
- Jennifer DenhartogClive$16K
- Wendianne WilsonUrbandale$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.